CN114341118A - 前列腺特异性膜抗原(psma)配体及其用途 - Google Patents

前列腺特异性膜抗原(psma)配体及其用途 Download PDF

Info

Publication number
CN114341118A
CN114341118A CN202080047295.1A CN202080047295A CN114341118A CN 114341118 A CN114341118 A CN 114341118A CN 202080047295 A CN202080047295 A CN 202080047295A CN 114341118 A CN114341118 A CN 114341118A
Authority
CN
China
Prior art keywords
compound
formula
psma
compounds
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080047295.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·F·马里亚尼
L·富加扎
D·奇科
M·G·庞培
S·拉伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Accelerator Applications Italy SRL
Johns Hopkins University
Original Assignee
Advanced Accelerator Applications Italy SRL
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications Italy SRL, Johns Hopkins University filed Critical Advanced Accelerator Applications Italy SRL
Priority to CN202510573926.8A priority Critical patent/CN120441498A/zh
Priority to CN202510573851.3A priority patent/CN120441497A/zh
Publication of CN114341118A publication Critical patent/CN114341118A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080047295.1A 2019-07-02 2020-06-30 前列腺特异性膜抗原(psma)配体及其用途 Pending CN114341118A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202510573926.8A CN120441498A (zh) 2019-07-02 2020-06-30 前列腺特异性膜抗原（psma）配体及其用途
CN202510573851.3A CN120441497A (zh) 2019-07-02 2020-06-30 前列腺特异性膜抗原（psma）配体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19184015 2019-07-02
EP19184015.6 2019-07-02
PCT/EP2020/068386 WO2021001360A1 (en) 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510573926.8A Division CN120441498A (zh) 2019-07-02 2020-06-30 前列腺特异性膜抗原（psma）配体及其用途
CN202510573851.3A Division CN120441497A (zh) 2019-07-02 2020-06-30 前列腺特异性膜抗原（psma）配体及其用途

Publications (1)

Publication Number Publication Date
CN114341118A true CN114341118A (zh) 2022-04-12

Family

ID=67145647

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080047295.1A Pending CN114341118A (zh) 2019-07-02 2020-06-30 前列腺特异性膜抗原(psma)配体及其用途
CN202510573926.8A Pending CN120441498A (zh) 2019-07-02 2020-06-30 前列腺特异性膜抗原（psma）配体及其用途
CN202510573851.3A Pending CN120441497A (zh) 2019-07-02 2020-06-30 前列腺特异性膜抗原（psma）配体及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510573926.8A Pending CN120441498A (zh) 2019-07-02 2020-06-30 前列腺特异性膜抗原（psma）配体及其用途
CN202510573851.3A Pending CN120441497A (zh) 2019-07-02 2020-06-30 前列腺特异性膜抗原（psma）配体及其用途

Country Status (16)

Country Link
US (1) US20230226227A1 (https=)
EP (1) EP3993837A1 (https=)
JP (2) JP7805170B2 (https=)
KR (1) KR20220044496A (https=)
CN (3) CN114341118A (https=)
AR (1) AR119331A1 (https=)
AU (3) AU2020299974A1 (https=)
BR (1) BR112021026812A2 (https=)
CA (1) CA3144557A1 (https=)
CL (1) CL2021003525A1 (https=)
CO (1) CO2021017708A2 (https=)
IL (1) IL289039B1 (https=)
MX (1) MX2022000136A (https=)
PH (1) PH12021553284A1 (https=)
TW (1) TW202114742A (https=)
WO (1) WO2021001360A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297323A (en) * 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
WO2022108992A1 (en) * 2020-11-17 2022-05-27 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
CN121604981A (zh) 2023-07-21 2026-03-03 诺华公司 靶向psma的放射性配体治疗方案
WO2025125469A1 (en) 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636924A (zh) * 2013-10-18 2016-06-01 德国癌症研究中心 前列腺特异性膜抗原(psma)的标记的抑制剂，它们作为显影剂和用于治疗前列腺癌的药剂的用途
WO2017165473A1 (en) * 2016-03-22 2017-09-28 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
WO2018222778A1 (en) * 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2415709A1 (en) 2000-07-11 2003-01-10 Bml, Inc. Remedies for bone diseases
AU2012294639B2 (en) * 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
US11813340B2 (en) * 2018-02-06 2023-11-14 The Johns Hopkins University PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
US20210338846A1 (en) * 2018-07-30 2021-11-04 The Johns Hopkins University Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636924A (zh) * 2013-10-18 2016-06-01 德国癌症研究中心 前列腺特异性膜抗原(psma)的标记的抑制剂，它们作为显影剂和用于治疗前列腺癌的药剂的用途
WO2017165473A1 (en) * 2016-03-22 2017-09-28 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
CN109311827A (zh) * 2016-03-22 2019-02-05 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
WO2018222778A1 (en) * 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Also Published As

Publication number Publication date
AU2024200850A1 (en) 2024-02-29
CO2021017708A2 (es) 2022-05-20
AU2020299974A1 (en) 2022-01-27
CN120441498A (zh) 2025-08-08
JP7805170B2 (ja) 2026-01-23
IL289039B1 (en) 2026-03-01
BR112021026812A2 (pt) 2022-02-22
MX2022000136A (es) 2022-04-27
PH12021553284A1 (en) 2022-08-01
AU2024200850B2 (en) 2025-09-04
AU2025271182A1 (en) 2025-12-18
US20230226227A1 (en) 2023-07-20
JP2022538478A (ja) 2022-09-02
AR119331A1 (es) 2021-12-09
IL289039A (en) 2022-02-01
CL2021003525A1 (es) 2022-10-21
KR20220044496A (ko) 2022-04-08
EP3993837A1 (en) 2022-05-11
JP2025165975A (ja) 2025-11-05
TW202114742A (zh) 2021-04-16
WO2021001360A1 (en) 2021-01-07
CN120441497A (zh) 2025-08-08
CA3144557A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
JP7036774B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
US20250057993A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
US12054458B2 (en) 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
EP3209336B1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN114341118A (zh) 前列腺特异性膜抗原(psma)配体及其用途
ligan et al. 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals
CN106660943A (zh) 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
JP2022513630A (ja) 治療および画像化のためのデンドリマー
EP4474379A1 (en) Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative
CN109789207A (zh) 用于原位免疫调节的癌症疫苗接种的靶向放射治疗螯合物
JP2024532521A (ja) ペプチド－尿素誘導体、それを含む医薬組成物、及びそれらの使用
EP3011976A1 (en) 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
CN114096526A (zh) 前列腺特异性膜抗原（psma）配体及其用途
CN119874628B (zh) 一种含氮化合物及其制备方法与用途
CN120349373A (zh) 一种含氮化合物及其制备方法与用途
CN119112891A (zh) 基于联合给药策略的靶向parp诊疗一体化试剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination